|
11 Companies |
|
4 Products |
|
4 Products |
|
8 Mechanisms of Action |
|
0 Trials |
|
59 News |
|
| 12» |
- | NN1213 / Novo Nordisk
Trial completion, Trial completion date: Polygen Defi-Alpha: Genetic Polymorphisms Study in Children With Alpha-1 Antitrypsin Deficiency, Included in the DEFI-ALPHA Cohort (clinicaltrials.gov) - Nov 7, 2018
P=N/A, N=296, Completed, Sponsor: Hospices Civils de Lyon
Recruiting --> Completed | Trial completion date: Dec 2018 --> Nov 2017
- | NN1213 / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: AATD: Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency (clinicaltrials.gov) - Aug 1, 2018
P=N/A, N=100, Completed, Sponsor: Fondazione Salvatore Maugeri
Recruiting --> Completed | Trial completion date: Dec 2018 --> Nov 2017 Not yet recruiting --> Completed | Trial completion date: Oct 2017 --> Apr 2018 | Trial primary completion date: Mar 2017 --> Apr 2018
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date: The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency (clinicaltrials.gov) - Jul 16, 2018
P=N/A, N=43, Completed, Sponsor: Biocerna LLC
Not yet recruiting --> Completed | Trial completion date: Oct 2017 --> Apr 2018 | Trial primary completion date: Mar 2017 --> Apr 2018 Recruiting --> Completed | N=90 --> 43 | Trial completion date: Dec 2019 --> Apr 2018 | Trial primary completion date: Dec 2018 --> Apr 2018
- | Enrollment change: Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability (clinicaltrials.gov) - Jul 13, 2018
P=N/A, N=11, Terminated, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Completed | N=90 --> 43 | Trial completion date: Dec 2019 --> Apr 2018 | Trial primary completion date: Dec 2018 --> Apr 2018 N=103 --> 11
- | Trial completion, Enrollment change: Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability (clinicaltrials.gov) - Apr 20, 2018
P=N/A, N=24, Completed, Sponsor: University of North Carolina, Chapel Hill
N=103 --> 11 Suspended --> Completed | N=10 --> 24
- ALN-AAT / Alnylam
Trial termination: A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease (clinicaltrials.gov) - Mar 19, 2018
P1/2, N=26, Terminated, Sponsor: Alnylam Pharmaceuticals
Suspended --> Completed | N=10 --> 24 Active, not recruiting --> Terminated; Observation of low incidence of asymptomatic, transiently elevated liver enzymes in a subset of study subjects
- | ALN-AAT / Alnylam
Enrollment change, Trial primary completion date: A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease (clinicaltrials.gov) - Nov 27, 2017
P1/2, N=26, Active, not recruiting, Sponsor: Alnylam Pharmaceuticals
Active, not recruiting --> Terminated; Observation of low incidence of asymptomatic, transiently elevated liver enzymes in a subset of study subjects N=66 --> 26 | Trial primary completion date: Dec 2015 --> Feb 2018
- Phase classification, Trial primary completion date: Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability (clinicaltrials.gov) - Nov 17, 2017
P=N/A, N=10, Suspended, Sponsor: University of North Carolina, Chapel Hill
N=66 --> 26 | Trial primary completion date: Dec 2015 --> Feb 2018 Phase classification: P2 --> P=N/A | Trial primary completion date: Jul 2017 --> Dec 2018
- | Prolastin-C (human alpha1-proteinase inhibitor IV) / Grifols, OrphanPacific
Trial termination: Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus (clinicaltrials.gov) - Oct 30, 2017
P2, N=76, Terminated, Sponsor: Grifols Therapeutics Inc.
Active, not recruiting --> Terminated; Wk 52 primary endpoint results would be unaffected by follow-up data so trial was discontinued prior to wk 104. No safety data was collected after wk 52.
- || ALN-AAT / Alnylam
Trial primary completion date: A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease (clinicaltrials.gov) - Jun 5, 2017
P1/2, N=66, Active, not recruiting, Sponsor: Alnylam Pharmaceuticals
No safety data was collected after wk 52. Trial primary completion date: Jan 2017 --> Dec 2015
- ARC-AAT / Arrowhead
Trial primary completion date, Biopsy: Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels (clinicaltrials.gov) - May 18, 2017
P2, N=0, Withdrawn, Sponsor: Arrowhead Pharmaceuticals
Trial primary completion date: Jan 2017 --> Dec 2015 Trial primary completion date: Dec 2017 --> Nov 2016
- | Enrollment change, Trial withdrawal: LuReCAA: Lung Volume Reduction Coils for Emphysema in Alpha-1 Antitrypsin Deficiency (clinicaltrials.gov) - May 2, 2017
P=N/A, N=0, Withdrawn, Sponsor: University Hospital, Saarland
Trial primary completion date: Dec 2017 --> Nov 2016 N=20 --> 0 | Recruiting --> Withdrawn
- Trial primary completion date: Polygen Defi-Alpha: Genetic Polymorphisms Study in Children With Alpha-1 Antitrypsin Deficiency, Included in the DEFI-ALPHA Cohort (clinicaltrials.gov) - Feb 11, 2017
P=N/A, N=420, Recruiting, Sponsor: Hospices Civils de Lyon
N=20 --> 0 | Recruiting --> Withdrawn Trial primary completion date: Dec 2016 --> Dec 2017
- New trial: The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency (clinicaltrials.gov) - Feb 1, 2017
P=N/A, N=90, Recruiting, Sponsor: Biocerna LLC
- ARC-AAT / Arrowhead
Trial termination: A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD) (clinicaltrials.gov) - Jan 6, 2017
P1, N=65, Terminated, Sponsor: Arrowhead Pharmaceuticals
Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Terminated; Company decision to terminate the trial
- ARC-AAT / Arrowhead
Trial withdrawal, Biopsy: Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels (clinicaltrials.gov) - Dec 4, 2016
P2, N=0, Withdrawn, Sponsor: Arrowhead Pharmaceuticals
Recruiting --> Terminated; Company decision to terminate the trial Not yet recruiting --> Withdrawn
- || Prolastin-C (human alpha1-proteinase inhibitor IV) / Grifols, OrphanPacific
Trial primary completion date: Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus (clinicaltrials.gov) - Oct 17, 2016
P2, N=76, Active, not recruiting, Sponsor: Grifols Therapeutics Inc.
Not yet recruiting --> Withdrawn Trial primary completion date: May 2016 --> Dec 2016
- ARC-AAT / Arrowhead
New P2 trial, Biopsy: Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels (clinicaltrials.gov) - Sep 14, 2016
P2, N=8, Not yet recruiting, Sponsor: Arrowhead Pharmaceuticals
- Phase classification, Enrollment change, Trial termination, Trial primary completion date: Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability (clinicaltrials.gov) - Jul 13, 2016
P=N/A, N=103, Terminated, Sponsor: University of North Carolina, Chapel Hill
Trial primary completion date: May 2016 --> Dec 2016 Phase classification: P2 --> P=N/A | N=20 --> 103 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2016 --> Dec 2012; Funding exhausted.
- ||| ALN-AAT / Alnylam
Enrollment closed: A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease (clinicaltrials.gov) - May 16, 2016
P1/2, N=66, Active, not recruiting, Sponsor: Alnylam Pharmaceuticals
Phase classification: P2 --> P=N/A | N=20 --> 103 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2016 --> Dec 2012; Funding exhausted. Recruiting --> Active, not recruiting
- ARC-AAT / Arrowhead
Enrollment change, Trial primary completion date: A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD) (clinicaltrials.gov) - Apr 27, 2016
P1, N=78, Recruiting, Sponsor: Arrowhead Pharmaceuticals
Recruiting --> Active, not recruiting N=48 --> 78 | Trial primary completion date: Aug 2016 --> Dec 2016
- Trial suspension: Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability (clinicaltrials.gov) - Apr 9, 2016
P2, N=10, Suspended, Sponsor: University of North Carolina, Chapel Hill
N=48 --> 78 | Trial primary completion date: Aug 2016 --> Dec 2016 Recruiting --> Suspended
- ||| Prolastin-C (human alpha1-proteinase inhibitor IV) / Grifols, OrphanPacific
Enrollment closed: Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus (clinicaltrials.gov) - Feb 11, 2016
P2, N=76, Active, not recruiting, Sponsor: Grifols Therapeutics Inc.
Recruiting --> Suspended Recruiting --> Active, not recruiting
- | alpha-1-antitrypsin inhalation (VR179) / Vectura, Grifols
Enrollment change: Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis (clinicaltrials.gov) - Feb 8, 2016
P2, N=30, Completed, Sponsor: Grifols Therapeutics Inc.
Recruiting --> Active, not recruiting N=41 --> 30
- || Prolastin-C (human alpha1-proteinase inhibitor IV) / Grifols, OrphanPacific
Trial completion: A Study to Assess Safety and PK of Liquid Alpha?-Proteinase Inhibitor (Human) in Treating Alpha?-Antitrypsin Deficiency (clinicaltrials.gov) - Feb 2, 2016
P2/3, N=32, Completed, Sponsor: Grifols Therapeutics Inc.
N=41 --> 30 Recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: GRADS Alpha-1: Genomic Research in Alpha-1 Antitrypsin Deficiency (clinicaltrials.gov) - Jan 15, 2016
P=N/A, N=140, Completed, Sponsor: University of Pittsburgh
Recruiting --> Completed Recruiting --> Completed | N=200 --> 140 | Trial primary completion date: Feb 2015 --> Jun 2015
- Trial completion, Trial primary completion date: GRADS Sarc: Genomic Research in Sarcoidosis (clinicaltrials.gov) - Jan 15, 2016
P=N/A, N=368, Completed, Sponsor: University of Pittsburgh
Recruiting --> Completed | N=200 --> 140 | Trial primary completion date: Feb 2015 --> Jun 2015 Recruiting --> Completed | Trial primary completion date: Feb 2015 --> Jun 2015
- Trial primary completion date: Polygen Defi-Alpha: Genetic Polymorphisms Study in Children With Alpha-1 Antitrypsin Deficiency, Included in the DEFI-ALPHA Cohort (clinicaltrials.gov) - Dec 15, 2015
P=N/A, N=400, Recruiting, Sponsor: Hospices Civils de Lyon
Recruiting --> Completed | Trial primary completion date: Feb 2015 --> Jun 2015 Trial primary completion date: Nov 2015 --> Dec 2016
- ARC-AAT / Arrowhead
Trial primary completion date: A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD) (clinicaltrials.gov) - Oct 22, 2015
P1, N=48, Recruiting, Sponsor: Arrowhead Research Corporation
Trial primary completion date: Nov 2015 --> Dec 2016 Trial primary completion date: Aug 2015 --> Aug 2016
- ||| New trial: AATD: Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency (clinicaltrials.gov) - Sep 14, 2015
P=N/A, N=100, Not yet recruiting, Sponsor: Fondazione Salvatore Maugeri
- Trial primary completion date: Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability (clinicaltrials.gov) - Aug 13, 2015
P2, N=10, Recruiting, Sponsor: University of North Carolina, Chapel Hill
Trial primary completion date: Aug 2015 --> Aug 2016 Trial primary completion date: Jul 2016 --> Jul 2017
- ||||| ALN-AAT / Alnylam
New P1/2 trial: A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease (clinicaltrials.gov) - Jul 21, 2015
P1/2, N=66, Recruiting, Sponsor: Alnylam Pharmaceuticals
- ARC-AAT / Arrowhead
Enrollment open: A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD) (clinicaltrials.gov) - Mar 18, 2015
P1, N=48, Recruiting, Sponsor: Arrowhead Research Corporation
Trial primary completion date: Jul 2016 --> Jul 2017 Not yet recruiting --> Recruiting
- | ARC-AAT / Arrowhead
New P1 trial: A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD) (clinicaltrials.gov) - Feb 18, 2015
P1, N=48, Not yet recruiting, Sponsor: Arrowhead Research Corporation
- rAAV1-CB-hAAT / BCM Families Foundation, AGTC
Trial completion, Trial primary completion date: Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin (AAT) Deficiency (clinicaltrials.gov) - Jan 17, 2015
P1/2, N=9, Completed, Sponsor: University of Massachusetts, Worcester
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Mar 2014 --> Jan 2015
- ||| Prolastin-C (human alpha1-proteinase inhibitor IV) / Grifols, OrphanPacific
New P2/3 trial: A Study to Assess Safety and PK of Liquid Alpha?-Proteinase Inhibitor (Human) in Treating Alpha?-Antitrypsin Deficiency (clinicaltrials.gov) - Nov 4, 2014
P2/3, N=30, Recruiting, Sponsor: Grifols Therapeutics Inc.
- Clinical: LuReCAA: Lung Volume Reduction Coils for Emphysema in Alpha-1 Antitrypsin Deficiency (clinicaltrials.gov) - Oct 23, 2014
P=N/A, N=20, Recruiting, Sponsor: University Hospital, Saarland
- Aralast NP (alpha 1-antitrypsin) / Omni Bio Pharma, Takeda
Enrollment change, Trial withdrawal, Trial primary completion date: A Research Trial of Aralast NP in New Onset Diabetes (RETAIN) - Part II (clinicaltrials.gov) - Oct 22, 2014
P2, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | Trial primary completion date: Mar 2014 --> Jan 2015 N=66 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Nov 2013 --> Aug 2014
- |||| Zemaira (human alpha-1 antitrypsin intravenous) / CSL Behring
Trial completion: Extension Study of Zemaira (clinicaltrials.gov) - Oct 2, 2014
P4, N=140, Completed, Sponsor: CSL Behring
N=66 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Nov 2013 --> Aug 2014 Active, not recruiting --> Completed
- |||| Prolastin-C (human alpha1-proteinase inhibitor IV) / Grifols, OrphanPacific
Enrollment open: Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus (clinicaltrials.gov) - Jul 14, 2014
P2, N=75, Recruiting, Sponsor: Grifols Therapeutics Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Enrollment closed: Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability (clinicaltrials.gov) - May 1, 2014
P2, N=20, Active, not recruiting, Sponsor: University of North Carolina, Chapel Hill
Not yet recruiting --> Recruiting Suspended --> Active, not recruiting
- ||||| Prolastin-C (human alpha1-proteinase inhibitor IV) / Grifols, OrphanPacific
New P2 trial: Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus (clinicaltrials.gov) - Mar 18, 2014
P2, N=75, Not yet recruiting, Sponsor: Grifols Therapeutics Inc.
- | NN1213 / Novo Nordisk
Trial completion: 4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency? (clinicaltrials.gov) - Feb 22, 2014
P2, N=12, Completed, Sponsor: University of Florida
Suspended --> Active, not recruiting No longer recruiting --> Completed
- Enrollment open: GRADS Alpha-1: Genomic Research in Alpha-1 Antitrypsin Deficiency (clinicaltrials.gov) - Jan 9, 2014
P=N/A, N=200, Recruiting, Sponsor: University of Pittsburgh
No longer recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment open: GRADS Sarc: Genomic Research in Sarcoidosis (clinicaltrials.gov) - Jan 9, 2014
P=N/A, N=400, Recruiting, Sponsor: University of Pittsburgh
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial completion: Effects of Exercise Training in Chronic Obstructive Pulmonary Disease Versus Alpha-1-Antitrypsin-deficiency-patients (clinicaltrials.gov) - Dec 15, 2013
P=N/A, N=20, Completed, Sponsor: Klinikum Berchtesgadener Land der Sch
Not yet recruiting --> Recruiting Recruiting --> Completed
- | alpha-1-antitrypsin inhalation (VR179) / Vectura, Grifols
Enrollment change: Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis (clinicaltrials.gov) - Nov 25, 2013
P2, N=41, Completed, Sponsor: Grifols Therapeutics Inc.
Recruiting --> Completed N=30 --> 41
- | alpha-1-antitrypsin inhalation (VR179) / Vectura, Grifols
Trial completion: Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis (clinicaltrials.gov) - Nov 25, 2013
P2, N=41, Completed, Sponsor: Grifols Therapeutics Inc.
N=30 --> 41 Active, not recruiting --> Completed
- Trial suspension: Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability (clinicaltrials.gov) - Oct 6, 2013
P2, N=20, Suspended, Sponsor: University of North Carolina, Chapel Hill
Active, not recruiting --> Completed Active, not recruiting --> Suspended
- Trial initiation date: Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability (clinicaltrials.gov) - Sep 4, 2013
P2, N=10, Recruiting, Sponsor: University of North Carolina, Chapel Hill
Active, not recruiting --> Suspended Initiation date: Jun 2013 --> Sep 2013